The Carmel Diagnostics Technology Platform measures oxidative stress and oxidizability for diagnosis, prognosis, and treatment monitoring of healthcare related phenomena.
The Company has developed TCL Analyzer™, which measures oxidative stress and can be adapted to numerous specific healthcare applications.
Carmel Diagnostics has focused on two major applications for its platform technology:
- Risk stratification of Congestive Heart Failure (CHF) patients, diagnosis of HF severity, and patients' prognosis.
- Embryo Selection - identifying the most viable embryos prior to embryo transfer in In-Vitro Fertilization procedures.
Pre-clinical validation tests of TCL Analyzer™ as a diagnostic device for CHF prognosis and for IVF embryo selection corroborated previous laboratory validation of TCL Technology.
TCL Technology Intellectual Property is protected by a US Patent from April 2002 and by similar patents granted in Japan, China, Canada, Russia, Israel, and Australia. Patent approval in the European Community is pending.